Literature DB >> 8993505

Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin.

X G Li1, P Haluska, Y H Hsiang, A Bharti, D W Kufe, E H Rubin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8993505     DOI： 10.1111/j.1749-6632.1996.tb26381.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN： 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  7 in total

Review 1.  Nuclear export of proteins and drug resistance in cancer.

Authors:  Joel G Turner; Jana Dawson; Daniel M Sullivan
Journal:  Biochem Pharmacol       Date:  2011-12-20       Impact factor: 5.858

Review 2.  Drug Resistance in Colorectal Cancer: From Mechanism to Clinic.

Authors:  Qianyu Wang; Xiaofei Shen; Gang Chen; Junfeng Du
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

Review 3.  Molecular markers in colorectal cancer: genetic bases for a customised treatment.

Authors:  E Casado; J De Castro; C Belda-Iniesta; P Cejas; J Feliu; M Sereno; M González-Barón
Journal:  Clin Transl Oncol       Date:  2007-09       Impact factor: 3.405

Review 4.  Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets.

Authors:  D C Gilbert; A J Chalmers; S F El-Khamisy
Journal:  Br J Cancer       Date:  2011-11-22       Impact factor: 7.640

5.  GEAR: A database of Genomic Elements Associated with drug Resistance.

Authors:  Yin-Ying Wang; Wei-Hua Chen; Pei-Pei Xiao; Wen-Bin Xie; Qibin Luo; Peer Bork; Xing-Ming Zhao
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

6.  Deciphering cellular states of innate tumor drug responses.

Authors:  Esther Graudens; Virginie Boulanger; Cindy Mollard; Régine Mariage-Samson; Xavier Barlet; Guilaine Grémy; Christine Couillault; Malika Lajémi; Dominique Piatier-Tonneau; Patrick Zaborski; Eric Eveno; Charles Auffray; Sandrine Imbeaud
Journal:  Genome Biol       Date:  2006-03-15       Impact factor: 13.583

7.  No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.

Authors:  L Calvet; A Santos; A Valent; M-J Terrier-Lacombe; P Opolon; J-L Merlin; G Aubert; J Morizet; J H M Schellens; J Bénard; G Vassal
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.